News | January 29, 2008

Aporo Licenses Biodegradable Polymers to Treat Structural Heart Disease

January 30, 2008 - Aporo Biomedical signed an exclusive global licensing agreement with mNEMOSCIENCE GmbH for its proprietary biodegradable shape memory polymers (BIO-SMP), enabling Aporo to offer devices with biodegradable closure features for treating structural heart diseases such as PFO and ASD.

Initially, Aporo will use these materials to treat Patent Foramen Ovale (PFO). In the future, the company will use the polymers in devices to treat Atrial Septal Defect (ASD), another structural heart disease, and for vascular closure after catheter-based interventional procedures.

Although minimally invasive catheter-based procedures are relatively short and can provide significant benefits to the patient, there is a growing desire among clinicians to avoid the potential complications and disadvantages from permanently implanting a large device in an otherwise healthy heart. Aporo Biomedical plans to address this concern by delivering a biodegradable device that closes the PFO without leaving a permanent implant.

For more information: www.aporobiomedical.com

Related Content

Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Dee Dee Wang, Henry Ford Hospital, 3D printing for cardiology, 3-D

Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.

Feature | 3-D Printing| March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care
News | Cath Lab| January 23, 2017
January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended thr
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Overlay Init